Actinium is a late-stage clinical pharma company developing targeted radiotherapies to deliver cancer-killing radiation with cell-level precision to treat patients with high unmet needs. Our pipeline is led by radiotherapies for targeted conditioning to selectively deplete disease or cancer and certain immune cells prior to a BMT, gene, or cell therapy (e.g., CAR-T) to enable engraftment of transplanted cells with minimal toxicities. The goal is to improve outcomes and access to curative treatments by reducing the non-targeted chemotherapy standardly used for conditioning.